Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 60, Issue 9, 2009, Pages 2794-2804

  Giannini, E H ^a   Ilowite, N T ^b   Lovell, D J ^a   Wallace, C A ^c   Rabinovich, C E ^d   Reiff, A ^e   Higgins, G ^f   Gottlieb, B ^g   Singer, N G ^h   Chon, Y ⁱ   Lin, S L ⁱ   Baumgartner, S W ⁱ  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^h CASE WESTERN RESERVE UNIVERSITY   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ABNORMAL THINKING; ABSCESS; ADOLESCENT; ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANXIETY; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ASTHMA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BEHAVIOR DISORDER; BLOOD CULTURE; BRONCHITIS; CHILD; CLINICAL TRIAL; COLITIS; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HERPES ZOSTER; HOSTILITY; HUMAN; HYDROURETER; IDIOPATHIC DISEASE; INFECTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NEURITIS; NEUROPATHY; OPEN STUDY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PERSONALITY DISORDER; PHARYNGITIS; POLYARTHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SCHOOL CHILD; SEPSIS; SIDE EFFECT; SINUSITIS; SKIN INFECTION; THYROIDITIS; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; UVEITIS; VIRUS INFECTION;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 69449090340     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24777     Document Type: Article

References (40)

1. Borchers AT, Selmi C, Cheema G, Keen CL, Shoenfeld Y, Gershwin ME. Juvenile idiopathic arthritis. Autoimmun Rev 2006;5:279-298
2. Oen KG, Cheang M. Epidemiology of chronic arthritis in childhood. Semin Arthritis Rheum 1996;26:575-591
3. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002;29:1989-1999 (Pubitemid 34988711)
4. Shaw KL, Southwood TR, Duffy CM, McDonagh JE, on behalf of the British Society of Paediatric and Adolescent Rheumatology, Children's Chronic Arthritis Association, Lady Hoare Trust for Physically Disabled Children, and Arthritis Care. Health-related quality of life in adolescents with juvenile idiopathic arthritis. Arthritis Rheum 2006;55:199-207.
5. Sallfors C, Hallberg LR, Fasth A. Well-being in children with juvenile chronic arthritis. Clin Exp Rheumatol 2004;22:125-130 (Pubitemid 38232820)
6. Adam V, St-Pierre Y, Fautrel B, Clarke AE, Duffy CM, Penrod JR. What is the impact of adolescent arthritis and rheumatism? Evidence from a national sample of Canadians. J Rheumatol 2005;32:354-361 (Pubitemid 40209137)
7. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Rheum Dis Clin North Am 2007;33:389-402.
8. Gutierrez-Suarez R, Pistorio A, Cespedes Cruz A, Norambuena X, Flato B, Rumba I, et al. Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas: the PRINTO multinational quality of life cohort study. Rheumatology (Oxford) 2007;46:314-320 (Pubitemid 46193945)
9. Oliveira S, Ravelli A, Pistorio A, Castell E, Malattia C, Prieur AM, et al, for the Pediatric Rheumatology International Trials Organization (PRINTO). Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum 2007;57:35-43.
10. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:393-399
11. Weiss JE, Ilowite NT. Juvenile idiopathic arthritis. Pediatr Clin North Am 2005;52:413-42, vi.
12. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109:109-115 (Pubitemid 34049434)
13. Niehues T, Horneff G, Michels H, Hock MS, Schuchmann L. Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int 2005;25:169-178 (Pubitemid 40576780)
14. Niehues T, Lankisch P. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Paediatr Drugs 2006;8:347-356 (Pubitemid 44912719)
15. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, et al. Cyclosporine A in juvenile idiopathic arthritis: results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006;24:599-605. (Pubitemid 44911259)
16. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995;13:113-118
17. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al, for the Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-3106
18. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-391
19. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-820
20. Enbrel (etanercept) full prescribing information. Thousand Oaks (CA): Immunex Corporation, marketed by Amgen and Wyeth Pharmaceuticals; 2008.
21. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-147 (Pubitemid 27306284)
22. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-2272 (Pubitemid 38924405)
23. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-1562 (Pubitemid 41532037)
24. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-1209 (Pubitemid 27430130)
25. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-769
26. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-1994 (Pubitemid 43877949)
27. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-1504
28. Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-692
29. Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007;28:153-156 (Pubitemid 350105867)
30. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-1101 (Pubitemid 36418252)
31. Van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003;5:R347-51.
32. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-525
33. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-392 (Pubitemid 38160763)
34. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-363 (Pubitemid 38198818)
35. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-2344 (Pubitemid 41640845)
36. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-1751 (Pubitemid 38725085)
37. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
38. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-1439 (Pubitemid 46764070)
39. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-653
40. Johnson DL, Jones KL, Chambers CD, the Organization of Teratology Information Specialists (OTIS) Collaborative Research Group. Pregnancy outcomes in women exposed to etanercept: the OTIS autoimmune diseases in pregnancy project. URL: http://www.otispregnancy.org/hm/download.php?id=12&client-id= 45